skip to search skip to navigation skip to main content


Despite huge effort and remarkable medical advances, a large number of cancers remain stubbornly difficult to treat.

Oncology is one of the most complex areas of medicine.

Every year, more than 3.5 million people in the European region are diagnosed with cancer and nearly two million die from the disease.¹ The need for new therapies is urgent. In 2006, Astellas made an enduring commitment to join the fight against cancer, channelling our expertise in developing innovative treatments to help meet the challenges faced by patients and their doctors. Since then, we have built a robust global oncology R&D network and established collaborations with key organisations at the forefront of cancer research.

Our goal is simple – to become a worldwide leader in the field of oncology. Through intense focus on the most promising new candidates and technologies, Astellas is developing a blossoming cancer drugs portfolio and unique pipeline. In the coming years, we plan to launch new treatments for a range of malignancies, including prostate, breast, lung and bladder cancers.

Prostate cancer is the fourth most common cancer worldwide and the second most common cancer in men.² Each year, 420,000 men across Europe are diagnosed with the disease and over 100,000 die from it.²

Find out more about prostate cancer at

1. International Agency for Research on Cancer. GLOBOCAN 20128 Fast Stats WHO European Region. Available at Last accessed 28 November 2016. /h6>
2. International Agency for Research on Cancer. GLOBOCAN 2012 Cancer Factsheet. Prostate Cancer Incidence, Mortality and Prevalence Worldwide in 20128 Summary. Available at Last accessed 28 November 2016.

Learn more about our therapy areas:

Terms of Use  |  Privacy Policy  |  Cookies Policy Copyright © 2017 Astellas Pharma Europe Ltd
APEL/16/0024/APEL January 2017